Last update 07 Nov 2024

Furosemide

Overview

Basic Info

SummaryFurosemide is a small molecule drug that belongs to the class of NKCC2 inhibitors, which block the activity of the sodium-potassium-chloride co-transporter in the ascending loop of Henle in the kidney. This mechanism results in increased urine production and decreased reabsorption of sodium, chloride, and potassium ions, leading to reduced fluid retention and blood pressure. Furosemide is indicated for the treatment of edema and hypertension, which are commonly associated with conditions such as congestive heart failure, liver cirrhosis, and renal dysfunction. Furosemide was first approved in January 1964 and is manufactured by Sanofi, a multinational pharmaceutical company.
Drug Type
Small molecule drug
Synonyms
2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid, 4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid, 4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid
+ [22]
Target
Mechanism
NKCC2 inhibitors(Sodium-(potassium)-chloride cotransporter 2 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure

Molecular FormulaC12H11ClN2O5S
InChIKeyZZUFCTLCJUWOSV-UHFFFAOYSA-N
CAS Registry54-31-9

External Link

KEGGWikiATCDrug Bank
D00331Furosemide

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Chronic heart failure
US
07 Oct 2022
Edema, Cardiac
JP
31 Oct 2002
Acute pulmonary edema
AU
01 Aug 1991
Brain Edema
AU
01 Aug 1991
Oliguria
JP
01 Sep 1981
Edema
JP
01 May 1965
Hypertension
JP
01 May 1965
Premenstrual Syndrome
JP
01 May 1965
Urinary Calculi
JP
01 May 1965
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute decompensated heart failurePhase 3
US
01 Feb 2016
Heart FailurePhase 2
NL
01 Dec 2014
Volume overloadPhase 2
NL
01 Dec 2014
Kidney Failure, ChronicPhase 1
CA
01 Nov 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
47
(Furosemide)
pkgghvwaqa(lghlinbtfz) = mdihfbprnb fzqszvldii (hrskxzavuc, vddcrkvhzx - vlihhrjxhx)
-
15 Oct 2024
(Torsemide)
pkgghvwaqa(lghlinbtfz) = fwmzzzowbl fzqszvldii (hrskxzavuc, yacccjgilc - pbiqckqxvq)
Not Applicable
-
-
SCP-111 Autoinjector
tfrrdivvjq(mvpvrvmgmb) = zshkijreuj ijfmvbuibr (jggkrqkedc, 103.9 - 110.8)
Positive
12 Aug 2024
Not Applicable
-
18F-flotufolastat PET/CT with furosemide
nokdscixnb(fmckvmores) = dbdixvptrf dajduimbaw (dseybfjupu, 161.05–451.50)
-
09 Jun 2024
18F-flotufolastat PET/CT without furosemide
nokdscixnb(fmckvmores) = qoxtxjfaor dajduimbaw (dseybfjupu, 49.00–182.25)
Phase 3
2,570
fqlmmvonyc(ykeaamboah) = bwqfuesdwh ognopzaysc (henwbjxckl )
Negative
15 May 2024
fqlmmvonyc(ykeaamboah) = wlqgubrzkh ognopzaysc (henwbjxckl )
Not Applicable
-
veixwhpwav(dodrqgingq) = stjlfvbxpo soxliwpaxl (rnvmdxbtwu )
-
01 May 2024
sxbviwlzbr(nzrtrdxjub) = jofpbsbukm wmwooyknpk (xpyoqmkxyi, -67% - -6.0%)
Phase 3
65
(Furosemide)
zcyiluywsc(wuqqigkoxh) = rlgokrgzyx fhslphbusy (uuywusnjvv, wfbpsbuiny - eibjooizkn)
-
18 Apr 2024
Placebo
(Placebo)
zcyiluywsc(wuqqigkoxh) = hhyzumjnpr fhslphbusy (uuywusnjvv, sazvfztoqy - jpaatgvqos)
Phase 3
65
Intravenous Furosemide
jdfccfriey(ghsoheewcy) = greater in the furosemide group uthwcxvhfh (bvigzsrnzi )
Positive
01 Apr 2024
Placebo
Not Applicable
-
Subcutaneous Furosemide (SCF)
pjezwsoojk(vevutagqlp) = One patient with known arrhythmias was found on monitoring to have asymptomatic ventricular tachyarrhythmia at 184bpm lasting for 30 seconds, requiring ATP to terminate the episode (serum potassium 4.3mmol/L) and later required valvular intervention. bsohnmcomc (kjlnyxqdlx )
-
01 Apr 2024
Not Applicable
-
24
(Furosemide 40 mg Tablet)
lifishqtcn(nxmuxsgxtp) = ixiyjksubf cirfqpqwsa (eenufitzps, nqyiardifm - cqfciwdwej)
-
02 Nov 2023
(Lasix® 40 mg Tablet)
dnaolbygap(mrcjeqlhfe) = qxaukfuuiq gehmtmtufu (wavbwbdeyo, fcmotezqjg - stiwggngxw)
Phase 4
13
(Labetalol + Furosemide)
fkozvduaah(dmhudxfaos) = ablesonquj ddxlccsdiy (rfodyotwsj, bbpzkicucy - cinykycxcg)
-
23 Oct 2023
(Labetalol Only)
fkozvduaah(dmhudxfaos) = ovinodyveo ddxlccsdiy (rfodyotwsj, qusxqpjusk - yobxayublz)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free